Drug Discovery Funding Opportunities

Cure SMA has invested more than $20 million in drug discovery since 2000. Our pre-clinical drug discovery program invests funding in innovative and promising projects that will lead directly to creating viable drugs for treating SMA.

Currently, we do not have any open funding opportunities for drug discovery. Please bookmark this page and check back for future funding announcements. In addition, please check our basic research funding opportunities page, through which we also fund early stage drug discovery programs.

Questions? Email research@curesma.org.

Past Funding

See more information about the drug discovery programs that we have funded:

Translational Advisory Council

Christine Brideau, PhD, Vice President, In Vitro Biology, WuXi AppTec, Preclinical Drug Development 

Arthur Burghes, PhD, Professor, The Ohio State University, SMA Biology  

Peter Grootenhuis, PhD, Senior Director, Vertex Pharmaceuticals, Medicinal Chemistry  

Peter Hodder, PhD,  Executive Director of Discovery Research, Amgen Inc., Assay Development and High-Throughput Screening 

Jim Inglese, PhD, Head, Laboratory of Assay Development & Screening Technology (ADST), National Center for Advancing Translational Sciences, Assay Development and High-Throughput Screening   

Joseph W. Lewcock, PhD, Head of Biology Discovery, Denali Therapeutics, Preclinical Drug Development

Brian Pollok, PhD, Prinicipal, Rapidan BioAdvisors, Assay Development

Timothy Reilly, PhD, DABT, Director, Bristol Myers Squibb, Toxicology

Lee Rubin, PhD, Director of Translational Medicine, Harvard Stem Cell Institute, Neuronal Assay Development and High-Throughput Screening 

Jasbir Singh, PhD, President, Jasin Discovery Solutions, Medicinal Chemist 

Charlotte Sumner, MD, Associate Professor, Johns Hopkins University, SMA Biology/Neurology  

Michael Vellard, PhD, Vice President of Research, Ultragenyx Pharmaceutical, Preclinical Drug Development 

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software